Stock of the Day

89BIO (ETNB)

$8.77

-$0.39 (-4.3%)

Market Cap: $1.28B

About 89BIO

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.

The company was incorporated in 2018 and is headquartered in San Francisco, California.

Recent News

• 89bio: Promising As Pegozafermin Nears Phase 3 Readout (seekingalpha.com)
• 89bio (ETNB) Q2 R&D Jumps 131% (fool.com)
• 89bio Reports Second Quarter 2025 Financial Results and Corporate Updates (globenewswire.com)